S282T was detected in 1/51 patients at relapse Conclusions: L159

S282T was detected in 1/51 patients at relapse. Conclusions: L159F and V321A NS5B substitutions emerge in a subset of patients

treated with SOF upon virologic failure. These HCV variants were observed mostly as minority viral variants and decreased in frequency during post-treatment follow-up indicating lower replication fitness in vivo as has been shown in vitro. The clinical significance of these variants and the mechanisms underlying their emergence given their lack of significant phenotypic changes to SOF remains to be determined. Disclosures: Evguenia S. Svarovskaia – Employment: Gilead Sciences Inc; Stock Shareholder: Selleck Sirolimus Gilead Sciences Inc Hadas Dvory-Sobol – Employment: Gilead Sciences; Stock Shareholder: Gilead Bortezomib molecular weight Sciences Brian Doehle – Employment: Gilead Sciences Edward J. Gane – Advisory Committees or Review Panels: Novira, AbbVie, Novartis, Gilead Sciences, Janssen Cilag, Vertex, Achillion, Tekmira, Merck, Ide-nix; Speaking and Teaching: AbbVie, Novartis, Gilead Sciences, Janssen Cilag Ira M. Jacobson – Consulting: Abbvie, Achillion, Boehringer Ingelheim, Bristol

Myers Squibb, Gilead, Idenix, Genentech, Merck, Janssen, Vertex; Grant/ Research Support: Abbvie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Novartis, Genentech, Merck, Janssen, Vertex; Speaking and Teaching: Bristol Myers Squibb, Gilead, Genentech, Vertex, Janssen David R. Nelson – Advisory Committees or Review Panels: Merck; Grant/Research Support: Abbot, BMS, 上海皓元医药股份有限公司 Beohringer Ingelheim, Gilead, Genentech, Merck, Bayer, Idenix, Vertex, Jansen Eric Lawitz – Advisory Committees or Review Panels: AbbVie, Achillion Pharmaceuticals, BioCryst, Biotica, Enanta, Idenix Pharmaceuticals, Janssen, Merck & Co, Novartis, Santaris Pharmaceuticals, Theravance, Vertex Pharmaceuticals; Grant/Research Support: AbbVie, Achillion Pharmaceuticals, Boehringer Ingel-heim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline,

Idenix Pharmaceuticals, Intercept Pharmaceuticals, Janssen, Merck & Co, Novartis, Presidio, Roche, Santaris Pharmaceuticals, Vertex Pharmaceuticals ; Speaking and Teaching: Gilead, Kadmon, Merck, Vertex Diana M. Brainard – Employment: Gilead Sciences; Stock Shareholder: Gilead Sciences John G. McHutchison – Employment: Gilead Sciences; Stock Shareholder: Gilead Sciences Michael D. Miller – Employment: Gilead Sciences, Inc.; Stock Shareholder: Gil-ead Sciences, Inc. Hongmei Mo – Employment: Gilead Science Inc Background: The cost-effectiveness of treatment for Hepatitis C (HCV) depends on the extent of reductions in the risk of liver transplantation, hepatocellular carcinoma (HCC), and all-cause mortality for people achieving Sustained Virological Response (SVR) during long-term follow up post-treatment, plus the risk of re-infection with HCV.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>